摘要
目的:探讨莉芙敏治疗妇科恶性肿瘤术后绝经症状的有效性。方法:26名妇科恶性肿瘤患者术后首次出现绝经症状,口服莉芙敏片20 mg/次,2次/d,口服药物12周。在用药4、8、12周后进行随访。疗效评价采用改良的Kupperman绝经指数(KMI)评分,以肝肾功能、血常规等实验室检查及不良事件作为安全性指标,将用药前后的数据进行比较。结果:26名患者治疗前KMI总分为(28.15±6.74),用药12周后为(11.46±4.08),较治疗前明显降低(P<0.05)。对单项指标治疗前后比较,发现性生活及泌尿系感染治疗前后无明显差异(P≥0.05),其余各项均明显降低(P<0.05)。用药后肝肾功能等实验室指标未见明显改变,且未发生严重不良反应。结论:莉芙敏可以有效缓解妇科恶性肿瘤术后绝经症状,且有较好的安全性。
Objective： To evaluate the efficacy of Remifemin for treatment of menopausal symptoms in patients with gynecological cancers after operation.Methods： Twenty-six patients with gynecological cancers,who firstly suffered menopausal symptoms after operation,took Remifemin tablet 20 mg per time and twice a day for 12 weeks.They were followed up at 4 weeks、8 weeks and 12 weeks of the treatment.Curative effect was evaluated by using the improved Kupperman menopause index（KMI） score.Laboratory examinations such as hepatic and renal function,blood routine examination and others and adverse events were took as the security index.The data before and after treatment were compared.Results： Total scores of KMI before the treatment were 28.15±6.74,and these after 12 weeks of the treatment were 11.46±4.08,which were significantly lower than those before the treatment（P0.05）.Compared in single item scores of KMI before and after the treatment,there was no statistical significance with sexual life and urinary system infection（P≥0.05）,and other single item scores of KMI were significantly lower（P0.05）.There were no remarkable changes in laboratory examinations such as hepatic and renal function and no serious adverse events.Conclusion： Remifemin can effectively relieve menopausal symptoms in patients with gynecological cancers after operation,and has good safety.
出处
《河南医学研究》
CAS
2013年第4期496-499,共4页
Henan Medical Research
关键词
莉芙敏
妇科恶性肿瘤
绝经
Remifemin
gynecological cancers
menopausal symptoms
